Patni Rajiv — SEC insider filings
SEC reporting owner CIK 1616200. 8 insider filings on record with FilingPulse; latest filed 2026-09-10.
Transaction summary — filings shown
Covers all 8 filings on record, filed 2023-06-14 to 2026-09-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 10.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| REATA PHARMACEUTICALS INC (RETA) | EVP, Chief R&D Officer | 2 | — | — | 4 |
| Quince Therapeutics, Inc. (QNCX) | Director | 3 | — | — | 3 |
| BioXcel Therapeutics, Inc. (BTAI) | Director | 2 | — | — | 2 |
| Septerna, Inc. (SEPN) | Chief Medical Officer | 1 | — | — | 1 |
Insider filings — Patni Rajiv
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-10 | 4 | Septerna, Inc. (SEPN) | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Quince Therapeutics, Inc. (QNCX) | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2025-01-16 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 44,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Quince Therapeutics, Inc. (QNCX) | Grant/award (A): 13,500 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Quince Therapeutics, Inc. (QNCX) | Grant/award (A): 54,000 (derivative) @ $0 | EDGAR |
| 2023-09-26 | 4 | REATA PHARMACEUTICALS INC (RETA) | Disposition to issuer (D): 45,000 · Disposition to issuer (D): 90,000 (derivative) | EDGAR |
| 2023-06-14 | 4 | REATA PHARMACEUTICALS INC (RETA) | Grant/award (A): 45,000 @ $0 · Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2022-05-23 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1616200 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs